Abstract Library

#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy

Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kim Y, Yoo C, Ryoo B, Ryu J,

Keywords: neuroendocrine tumor, lanreotide, somatostatin receptor, DOTATOC, positron emission tomography, prognosis,

#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.

Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Pommier R

Authors: Pommier R, Strosberg J, Singh S, Wolin E, Yao J,

Keywords: Everolimus, nonfunctional NET, prior chemotherapy,

#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)

Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: pusceddu s

Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,

Keywords: everolimus,

#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)

Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Markovich A, Odintsova A,

Keywords: neuroendocrine tumor, everolimus,

#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)

Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,

Keywords: targeted therapy, sorafenib, bevacizumab,